Tiziana Life Sciences’ (NASDAQ:TLSA) lock-up period will end on Monday, May 20th. Tiziana Life Sciences had issued 442,910 shares in its public offering on November 20th. The total size of the offering was $4,384,809 based on an initial share price of $9.90. After the expiration of the company’s lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.
TLSA opened at $8.18 on Monday. Tiziana Life Sciences has a 1-year low of $5.00 and a 1-year high of $12.17.
About Tiziana Life Sciences
Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of therapeutics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Milciclib (TZLS-201) that is in phase II clinical trials for epithelial thymic carcinoma and/or thymoma in patients previously treated with chemotherapy; and Foralumab (TZLS-401), a human anti-CD3 antibody, which completed phase IIa clinical trials for autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis, primary biliary cholangitis, ulcerative colitis, multiple sclerosis, autoimmune type-1 diabetes, inflammatory bowel diseases, and lupus.
Featured Article: Oversold
Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.